C TCR055
Alternative Names: AFP TCR-T; Alpha fetoprotein T Cell Receptor; C-TCR055Latest Information Update: 27 Nov 2023
At a glance
- Originator Augusta University
- Developer AbelZeta Pharma
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 28 Jan 2023 No recent reports of development identified for clinical-Phase-Unknown development in Liver-cancer in USA (Parenteral)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable, Second-line therapy or greater) in China (IV, Infusion)